Enbrel Near Psoriasis User Fee Goal; Amgen Looking At "Step Down" Dosing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase III psoriasis data for Amgen’s Enbrel show significant efficacy for a "step down" regimen combining initial loading doses of the tumor necrosis factor inhibitor with half-dose therapy over three months.